A new drug designed to fight chronic migraines could be on the market within a week.
The FDA approved Aimovig on Thursday.
It's designed to reduce the frequency of migraines which affect about 12% of Americans.
The drug works by blocking the activity of a genetic molecule involved in migraine attacks.
Patients will be able to administer the drug through monthly injections at home.
The drug requires a prescription it's expected to come with a price tag of $575, but may be covered by insurance.